performed gain-of-function genetic modifier screens and showed that MCL-1 and BCL-2 family (mainly BCL-2, BCL2L1, and BCL2L2) protein upregulation resulted in venetoclax resistance in CLL cells. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.